Second quarter sales for Johnson & Johnson's ($JNJ) medical devices and diagnostics division mirrored those reported in the first quarter, coming in relatively flat at $7.2 billion as sales in its vision and diabetes lines continued to decline due to price competition.
Johnson & Johnson is always the first Big Pharma to roll out quarterly results. So, investors and analysts watch J&J's numbers for hints about the rest of the industry. But these days, J&J is more of an anomaly than a leading indicator. Why? Its drug sales are growing--big time.
Private equity firms are sitting on a record amount of unspent cash--$1.2 trillion by some estimates. At the same time, Big Pharma companies are looking to cast off off-patent drugs and other old products. Could that make a match?
Boston Scientific's Guidant subsidiary faces more legal pushback in its ongoing breach-of-contract lawsuit against Johnson & Johnson, as a federal judge denied the company's request to toss out the case.
Jan van de Winkel The Danish biotech Genmab has won a $25 million milestone from its $1.1 billion collaboration deal with Johnson & Johnson ($JNJ) on the CD38 antibody daratumumab. The...
The potential nomination of Johnson & Johnson chief intellectual property counsel Philip Johnson as director of the U.S. Patent and Trademark Office suggests efforts to reform the patent system are dying, especially changes to rein in so called patent trolls.
Hiring ahead of and cutting after mergers is always tricky, but organizational change marches on. Post-merger Johnson & Johnson and pre-merger Covidien are both forging ahead, with cuts in J&J's DePuy Synthes and hiring for Covidien.
Back in 1989, a court order limited advertising claims for Advil, now owned by Pfizer. But does that order extend to Infants' Advil, which didn't exist at the time? Rival Johnson & Johnson says yes--and it's forced Pfizer to pull one of its ads for that very reason.
With more M&A, product development and restructuring on the horizon, med tech CEOs have their work cut out for them in the coming year. But for now, here's the breakdown of what they took home in 2013.
Johnson & Johnson's Janssen Pharmaceuticals unit has notified the FDA that it has made a business decision to discontinue the production of its antibiotic Levaquin.